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Abstract
Background—The role of insulin resistance (IR) on fibrosis progression in HCV patients has 
not been systematically evaluated. Therefore, this systemic review aimed to summarize the 
available epidemiologic evidence to evaluate the strength of association between IR and advanced 
liver fibrosis in these patients.
Methods—We performed a systemic literature search in PubMed, OvidSP and MEDLINE from 
January 1990 to April 2015 without language restriction using the following search terms: insulin 
resistance, liver fibrosis, cirrhosis, diabetes mellitus and chronic hepatitis C. Publication bias was 
assessed using the Begg and Egger’s tests and with a visual inspection of funnel plot. All analyses 
were performed using Comprehensive Meta-Analysis version 2 software.
Results—A total of 3,659 participants with HCV infection from 14 studies were included in the 
analysis. After adjusting for publication bias, the RR for significant hepatic fibrosis among HCV 
subjects with IR was 1.63 (95% CI 1.34-2.01). Subgroup analysis by genotypes showed RR of 
2.16 (95% CI 1.52-3.06) for genotype 1; however, the association was no longer significant when 
we analyzed the data for HCV genotype 3; RR 1.40 (95% CI 0.8-2.45).
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Conclusion—Our study showed significant association between IR and significant hepatic 
fibrosis in patients with HCV genotype 1 infection.
Keywords
insulin resistance; liver fibrosis; chronic hepatitis C
INTRODUCTION
Hepatitis C virus (HCV) infection is a major global public health problem and it is estimated 
that ~2%-3% of the world population are infected with the virus1. It can now be successfully 
eradicated with the new therapeutic regimens; which are safe and highly efficacious2. 
However, the cost of these new drugs prohibits their use in many countries with limited 
resources around the world1. Undoubtedly, the morbidity and mortality from HCV infection 
continue to increase1.
Most patients who acquire HCV develop chronic HCV infection. However, the rate of 
disease progression from the time of infection till the development of advanced fibrosis or 
cirrhosis is variable3. In fact, the natural history of chronic HCV infection is difficult to 
determine because of the difficulty in estimating the time and duration of infection and other 
factors that can affect disease course. Though the mechanism is poorly understood, it is 
likely that both host and viral factors play an important role in the disease progression. 
Several factors have been reported to influence the fibrosis progression, including age4, 
ethnic background5, gender6, and alcohol use7.
Recent epidemiological studies suggested that HCV infection is an independent predictor for 
the development of type 2 diabetes mellitus (DM), and that type 2 DM is more prevalent 
among patients with chronic HCV infection than in those with other causes of liver 
diseases8–10. It is likely that the HCV itself or the inflammatory response to HCV infection 
contributes to the development of insulin resistance (IR) and thus increasing the risk for type 
2 DM11. The presence of IR and type 2 DM are independent predictors of severe fibrosis in 
patients with non-alcoholic fatty liver disease12, 13. The role of IR and advanced fibrosis in 
HCV patients has not been systematically evaluated. Therefore, this systemic review aimed 
to summarize the available epidemiologic evidence to evaluate the strength of association 
between IR and liver fibrosis in these patients.
METHODS
Study selection/search Strategy
We performed a systemic literature search in PubMed, OvidSP and MEDLINE from January 
1990 to April 2015 without language restriction using the following search terms: insulin 
resistance, liver fibrosis, cirrhosis, diabetes mellitus and chronic hepatitis C. The reference 
list of each included study was comprehensively searched to further identify relevant 
studies. The process of systematic review was conducted in adherence to standards of 
quality for reporting meta-analyses14.
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Inclusion and exclusion criteria
Relevant studies were included if they met the following criteria: (1) the studies were either 
case-control or cohort study designs; (2) the study participants were ≥ 18 years old; and (3) 
the relative risk (RR) estimate or odds ratio was reported for significant hepatic fibrosis in 
those with HCV infection.
Definition of hepatic fibrosis/cirrhosis
The following pathological classification for hepatic fibrosis was used; METAVIR, Scheuer, 
Ishak and histological activity index (HAI)4, 15–17. METAVIR scoring system was 
specifically designed for patients with HCV infection4. The fibrosis score is assigned a 
number from F0-F4 where F3-F4 representing advanced fibrosis. Scheuer classification 
defines stages of fibrosis from 0 to 4 where stages 2-4 indicate significant17. Ishak scale 
assesses liver fibrosis in 7 categories, ranging from normal (stage 0) to cirrhosis (stage 6)15. 
For this scoring system, stages 4-6 indicate significant fibrosis. Lastly, HAI classifies 
fibrosis from stage A to D and gives a score to each stage where score 3 or more indicates 
advanced fibrosis16.
Definition of insulin resistance
Insulin resistance was measured using the HOMA (Homeostasis Model Assessment). The 
cut-off for the HOMA to define the presence of IR in each study is shown in Table 1.
Data extraction
The following information were extracted from each study: publication data (such as first 
author’s last name and first name initials, year of publication and country of origin), sample 
size, participants’ demographic data, types of study design (case-control/cohort), number of 
cases and controls (for case-control studies), number of exposed and unexposed (for cohort 
studies), criteria used to define significant hepatic fibrosis stratified by different pathological 
classification, the levels of HOMA scores to define IR, risk estimates with their 
corresponding confidence intervals (CIs), and the covariates (if any) which were used in the 
multivariate modeling. We carefully reviewed the potential confounders; that might be 
associated with the risk of liver fibrosis in the studied population. In this study, odds ratios 
(ORs) from case-control studies were considered as estimate of relative risk. This is based 
on the assumption that the prevalence of HCV infection is <10%, and in this case the odds 
ratio and relative risk will be approximately the same. Two independent reviewers (SP and 
RJ) reviewed the studies and any discrepancies regarding inclusion/exclusion or risk 
estimates were resolved through the discussion by authors. We used Cohen’s kappa 
coefficient to assess the agreement among reviewers for inclusion/exclusion of specific 
studies18.
Assessment of methodological quality
To assess methodological quality of all the publications that were included in the final 
analysis, the Newcastle-Ottawa Scale was used19. The scale allocates stars, maximum of 
nine, for the following categories: quality of selection, comparability, exposure and outcome 
of study participants. Any studies with the scale < 5 were excluded.
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Statistical analysis
Summaries of relative risk (RR) estimates were evaluated using both fixed- and random-
effects methods. Initial analysis was performed to look for association between IR and 
significant liver fibrosis. We used Cochran’s Q-test and I2-statistic to determine the 
heterogeneity of the publications. Publication bias was assessed by (i) construction and 
visual inspection of funnel plot and (ii) employing the Egger’s and Begg and Mazumdar 
tests. Duval and Tweedie’s trim and fill method was utilized to obtain RR after adjustments 
of the publication bias. The p value of < 0.05 indicated statistical significance. All analyses 
were performed using Comprehensive Meta-analysis Version 2 (Biostat, Englewood, New 
Jersey)20.
RESULTS
Literature Search and Study Characteristics
The schematic diagram of the detailed literature selection is shown in Figure 1. We 
identified 380 studies from different databases, either in full publications or in abstract 
forms. After title appraisal and extensive review, 56 publications were considered to be 
potentially relevant. Of these, we excluded 8 review articles, 5 animal studies, 2 letters to the 
editors, 8 studies which described HIV/HCV co-infections, 2 studies with post liver 
transplant HCV patients, 1 clinical trial, and 12 studies which did not provide RR estimate. 
Four additional studies were excluded as they were cross sectional studies. Fourteen studies 
(12 cohort and 2 case-control studies) were considered for full article assessment and 
included in the final analysis.
Publication quality and bias
The Newcastle-Ottawa Scale (range, 1-9 stars) to assess the publication quality revealed 
average 5.6 stars for the twelve cohort studies and 6.5 for the two case-control studies. The 
detail for the scale for each study is shown in Table 1. Due to the presence of publication 
bias (funnel plot, Supplemental Fig 1, Begg and Mazumdar test: p = 0.04; Egger’s test: p = 
0.006), adjusted RR was used to report the results (Figure 2).
Association between insulin resistance and liver fibrosis
A total of 3,659 participants with HCV infection were included in the analysis. Of these, 12 
were cohort studies consisting of 3,259 subjects. Due to evidence of heterogeneity 
(Q=29.83, p value for heterogeneity 0.005, I2= 56.42%), we used random-effect model to 
report the pooled RR. The pooled RR for significant hepatic fibrosis among HCV subjects 
with IR was 1.89 (95% CI 1.54 -2.33) (Figure 2 and Fig S1). After adjusting for publication 
bias, the association remained significant with the adjusted RR 1.63 (95% CI 1.34-2.01).
We also performed subgroup analysis. Analysis of the 12 cohort studies showed RR of 2.02 
(95% CI 1.6-2.55, p<0.001). Subgroup analysis by genotypes showed RR of 2.16 (95% CI 
1.52-3.06) for Genotype 1 (Figures 3, 3 studies21–23); however, the association was no 
longer significant when we analyzed the data for HCV genotype 3 (3 studies21, 24, 25); RR 
1.40 (95% CI 0.8-2.45)(Figure 3 and Fig S2). We also analyzed the strength of association 
between IR and significant fibrosis, stratified by the different pathological classification. We 
Patel et al. Page 4
J Clin Gastroenterol. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
found that the RR was 1.80 (95%CI 1.28-2.52), when considered the studies using 
METAVIR method (Figure 4 and Fig S3, 6 studies26–31). The association was still 
significant when other classifications (Figure 5, 8 studies21–25, 30, 32, 33) were used, RR 1.73 
(95% CI 1.34-2.23).
Subgroup analysis was also performed based on the geographical location. There were no 
geographical differences in the association between IR and hepatic fibrosis; RR 1.69 (95% 
CI 1.32-2.17) for the studies from Europe and Australia (Figure S4, 10 
studies21–25, 27–29, 33, 34) and RR 1.90 (95% CI 1.27-2.83) for those from Asia (Figure S5, 4 
studies26, 30, 32).
DISCUSSION
The major findings of our study are the followings: 1) the presence of IR is a significant risk 
factor for advanced hepatic fibrosis in HCV patients and 2) whereas no association is 
observed for those infected with HCV genotype 3, the risk for significant fibrosis is 
increased for those infected with HCV genotype 1.
Association between hepatitis C infection and IR
The causal relationship of HCV infection and IR development has been demonstrated by the 
increased prevalence of IR in chronic HCV infection. The prevalence of IR in those infected 
with HCV is significantly higher than that in the general population35, 36. The mechanism of 
HCV-induced IR is complex. Following inflammatory response in the liver to HCV 
infection, a profound impairment of insulin signaling occurs at the level of insulin receptor 
substrate (IRS) tyrosine phosphorylation and phosphoinositide 3-kinase activation37. The 
increase in the levels of tumor necrotic factor-alpha by HCV core protein may also lead to 
proteasomal degradation of IRS1 and IRS2, resulting in the alteration of insulin function and 
the development of IR37.
In addition to the direct effect of HCV on insulin signaling, the development of IR can also 
mediated through hepatic steatosis. This can coexist with HCV, regardless of genotype, in 
patients with risk factors such as obesity and hyperlipidemia. Hepatic steatosis can also be 
related to the direct hepatopathic effect of genotype 3 viral infection38. In this scenario, the 
relationship between IR and HCV infection is bidirectional37; HCV induces steatosis and the 
latter could also cause IR39. HCV-associated hepatic steatosis is mainly virus-induced in 
genotype 3 infected patients due to the impairment in very low-density lipoprotein (VLDL) 
secretion38. However, in non-genotype 3, the development of IR is likely play a major role 
in steatosis37, 38.
Insulin resistance and hepatic fibrosis
Once developed, IR plays an important role in promoting hepatic fibrosis. Hyperinsulinemic 
state associated with IR directly activates stellate cells47–50. Furthermore, IR-induced 
hepatic lipid accumulation and generation of ROS can also indirectly activate stellate cells 
and initiate the cellular signaling cascades triggering hepatic fibrosis. Our findings that the 
progression of fibrosis in patients with IR is genotype-specific deserve further comments. 
Although the interference with the insulin sensitivity shows some HCV genotype-
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specificity, IR has been reported to occur in all HCV genotypes, but to a different 
extent37, 40. Patients infected with the genotype 3 virus have a lower prevalence of IR when 
compared with those infected with the other viral genotypes, even after adjustment for the 
effects of body mass index (BMI) and other confounders41, 42. However, genotype 1 
infection was found to be a significant determinant of severe IR, even in patients without 
underlying diabetes mellitus37. The effect of different genotypes of HCV on the severity of 
IR is likely explained our findings.
Limitation
Our systemic review has some limitations. First, there are factors which were not taken into 
consideration for the adjusted RR analysis such as age, gender, body mass index, duration of 
HCV infection and family history, primarily due to unavailability of these data in the 
original studies. Second, information on the history of alcohol intake was not uniformly 
provided. In the studies that mentioned alcohol intake, there were discrepancies in the 
amount as well as the cut-off levels for hazardous alcohol use. One study excluded any 
amount of alcohol users23 while others26, 28, 33, 34 used different levels of alcohol intake as 
the cut-off and one study31 did not consider alcohol consumption in exclusion criteria.
Summary and Clinical implications
This study elucidates the important relation for a genotype-specific association between IR 
and significant fibrosis in patients with HCV infection. Improvement in IR either by weight 
loss, life style change or insulin sensitizer can significantly improve SVR rates and 
treatment outcomes43. At present, it is unclear how insulin resistance will impact the 
response to treatment with the newly effective anti-viral agents for HCV. However, given 
the limited access to these new medications in other parts of the world, strategies to improve 
insulin sensitivity should be explored as they might mitigate against the progression of 
fibrosis.
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Figure 1. 
Schematic diagram for study selection of the relevant articles
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Figure 2. 
Forest plot of meta-analyses demonstrating the association between IR and significant 
fibrosis of all 14 studies
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Figure 3. 
Forest plot demonstrating association between IR and significant fibrosis, subgroup analysis 
stratified by genotypes
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Figure 4. 
Forest plot demonstrating association between IR and significant fibrosis, subgroup analysis 
for the studies using METAVIR as the pathological classification for fibrosis
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Figure 5. 
Forest plot demonstrating association between IR and significant fibrosis, subgroup analysis 
for the studies using non-METAVIR methods as the pathological classification for fibrosis
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